The IQPC PharmaTrace Summit will be held on June 4-6 in Princeton, NJ. In preparation for the event, IQPC asked four industry veterans to respond to a set of forward-looking questions to get a glimpse of the future of serialization and track & trace in the US pharma supply chain. The four include:
- Jeff Denton, Senior Director, IT Global Secure Supply Chain with AmerisourceBergen Corporation, one of the “Big-3” wholesale distributors in the United States,
- Andrew Meyer, Sr. Systems Analyst Traceability Lead, NC Mutual Wholesale Drug Company,
- Brian Tarantino, Former Lead, Global Product Serialization, Merck & Co., and
- Tharuvai Ramesh VP, Commercial Manufacturing & Supply Chain Neurocrine Biosciences.
The results are revealing. Get a copy of the interviews here.
As the pharmaceutical industry prepares itself for serialization and the requirements beyond, many questions arise regarding best practices that will ensure product traceability throughout the supply chain and compliance on an international scale, AND, value beyond compliance. At the same time, full serialization will likely impact the operation of the pharma supply chain in profound ways—some predictable, some less so. In these interviews, IQPC is leaning on the expert opinions of top pharmaceutical supply chain professionals for their thoughts on that future.
The conversation will continue at IQPC’s PharmaTrace Summit. Summit speakers include experts from AstraZeneca, Walgreens, Mayne Pharma, Bristol Meyers Squibb, United Therapeutics, Bell and Howell, FFF Enterprises, West-Ward Pharmaceuticals, the Center for Supply Chain Studies, GS1 US and more. These speakers will explore every aspect of this important industry transformation at the Pharmaceutical Traceability Forum. Don’t miss it.